Etrasimod for Eczema

Recruiting in Palo Alto (17 mi)

+121 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Pfizer

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a daily pill called etrasimod to treat adults with moderate to severe eczema who haven't had success with other treatments. The study will compare the effects of etrasimod to see if it is safe and effective. Participants will have periodic clinic visits to monitor their health and symptoms.

Research Team

Pfizer CT.gov Call Center

Principal Investigator

Pfizer

Eligibility Criteria

Adults aged 18-80 with moderate to severe atopic dermatitis (AD), also known as eczema, who have not seen improvement after trying systemic therapies. Participants must have had AD for at least a year and be willing to use daily moisturizers throughout the study.

Inclusion Criteria

I have been diagnosed with chronic eczema for over a year.

I am between 18 and 80 years old.

My eczema is moderate to severe, covering more than 10% of my body.

See 2 more

Exclusion Criteria

I do not have a serious infection or need treatment for one that could affect the trial.

You are allergic to etrasimod or any of the ingredients in the medication.

You have a medical or mental health condition, or recent thoughts of hurting yourself, that could make it risky for you to join the study.

See 1 more

Treatment Details

Interventions

Etrasimod (Sphingosine-1-Phosphate Receptor Modulator)
Placebo (Other)

Trial OverviewThe trial is testing Etrasimod, an oral medication, against a placebo in adults with AD. Part 1 randomly assigns participants to either drug or placebo for 16 weeks; some may continue Etrasimod for another 52 weeks. Part 2 involves all participants taking Etrasimod for one year.

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: etrasimodExperimental Treatment1 Intervention

2 mg, oral tablet, once daily

Group II: Placebo (Part 1 DB period only)Placebo Group1 Intervention

Oral sham comparator